Jessica Thompson

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial | Breast Cancer | JAMA | JAMA Network #SABCS24 ⁦@OncoAlert ⁦@ALLIANCE_org⁩ jamanetwork.com/journals/jama/…

So many informative & engaging sessions at this year's #ASBrS24! Also excited to officially ✔️off first project as PI - hopefully the geographic reach of breast specialty services can be further expanded to high risk individuals by means of telemedicine offerings in the future!

It’s time to update our counseling! BCT may have a better survival and has equivalent recurrence to mastectomy. #ASBRS24

🔥📄 Hot off the @JCO_ASCO press‼️ The @ASCO guideline on germline testing in patients with #BreastCancer 👏Congrats to all on this important work! @FilipaLynce @ibedrosian1 @MarkRobsonMD @SidYadavMD @AchatzIsabel @DrJudyBoughey @curijoey @force4sue pubmed.ncbi.nlm.nih.gov/38175972/

2023 was an outstanding year for breast cancer research As we start wrapping up #SABCS23, we need to think about how to incorporate what we learned in the clinic and future research. Looking forward to what is yet to come to improve outcomes for our patients! @OncoAlert #BCSM

Less than a week away until you can learn practical tips and tricks to help you get the most out of your fellowship! Don't miss this opportunity to maximize your potential 📈 ow.ly/rpcP50PC8rk

Which should be the duration of adjuvant endocrine treatment for early-stage HR+ breast cancer? @MichaelGnant nicely recapitulates the evidence & highlights the recent votes by the St. Gallen panel, with fairly clear answers. #ASCO23

#ASCO23 #BreastCancer Poster Session: ASCENT-05/OptimICE-RD: Phase 3 study of adjuvant sacituzumab govitecan + pembro vs pembro ± capecitabine in patients with #TNBC and residual disease after neoadjuvant therapy and surgery. @stolaney1 @DrLisaCarey #225748" target="_blank" rel="nofollow noopener">meetings.asco.org/2023-asco-annu…

Did you know there are 13 types of #breastcancer? In this video I go through them all, and as a bonus, I talk about the 5 ways it can be described - stage, grade etc What is Breast Cancer? youtu.be/2sK4myDbI30 via @YouTube

.@ClaraRFarley1 beautifully presents @MDAndersonNews study on factors predicting 4 or more positive nodes in cN0 HR+/Her2- breast cancer. Important data as we try to better predict nodal burden which can impact systemic therapy decisions #ASBrS23 @ASBrS

Strong start to #ASBRS2023 with thoughtful presentations highlighting controversial issues in breast surgery @ASBrS @puneetsinghmd @jenniferbellon2

Dr. Anita Mamtani @MSKCancerCenter presents on axillary management in cT1N0 TNBC & Her2+ breast ca. These patients may be safely selected to undergo upfront surgery w/o concern that many will be node positive & would have benefited from de-escalation of axilla w/ NACT. #SSO2023

Calling all TRAINEES attending @SocSurgOnc #SSO2023 - check out the Trainees Lounge, Rm 210. New this year we will have representatives from many CGSO and Breast Fellowship Programs to learn about the programs and #network! See thread below for the programs participating:

Excellent new podcast from the @SocSurgOnc Fellows & Young Attendings Subcommittee — tips on preparing for the transition from trainee to faculty practice! @kwashingtonmd @bsparkmanMD @Jenn_Tseng #SSO_FYAS surgonctoday.libsyn.com/mastering-the-…

🔊⚠️🔊⚠️ In the latest poll, 70% considered the use of primary sustained endocrine therapy (ET) in HR+ HER2- in #breastcancer patients older than 70yrs. Let’s check recent evidence on that published at @AnnSurgOncol! 🧵🧵🧵

I’m starting a national campaign to stop calling tam/AIs “chemoprevention”. I’m 100% sure leads to pts declining therapy. “Hormone therapy” is also a misnomer. Let’s call it “estrogen blockers” bc patient understand this, are more likely to anticipate side effects. Who’s with me?

February 3 is National Women Physicians Day – an event that celebrates Elizabeth Blackwell’s birthday, who was the first female medical doctor in the United States. On this day, we say thank you to all of the women in medicine who are making a difference around the world. #NWPD

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial ascopubs.org/doi/10.1200/JC… #bcsm

New editorial from @DrAnnaWeiss and @TariKingMD in Annals of Surgical Oncology. ➡️➡️ Local Regional Recurrence Rates Are Low Following Neoadjuvant Endocrine Therapy: What Are the Remaining Barriers to its Widespread Adoption? ⬇️⬇️Read fulltext here: rdcu.be/c2UAz

As a community medical oncologist, here are my top 5⃣ to bring back to my patients Monday morning after #SABCS22 @SABCSSanAntonio @OncoAlert 1. POSITIVE 🤰 2. BabyTam 👶 3. Contralateral #bcsm in gene mutation carriers 4. RIGHT - ribo in aggressive MBC 5. TMC - neo platinum 🧵